CN1927394A - 口服重组幽门螺杆菌疫苗及其制备方法 - Google Patents
口服重组幽门螺杆菌疫苗及其制备方法 Download PDFInfo
- Publication number
- CN1927394A CN1927394A CNA2006100950940A CN200610095094A CN1927394A CN 1927394 A CN1927394 A CN 1927394A CN A2006100950940 A CNA2006100950940 A CN A2006100950940A CN 200610095094 A CN200610095094 A CN 200610095094A CN 1927394 A CN1927394 A CN 1927394A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- lta2b
- ureb
- protein
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 23
- 229940124723 Helicobacter pylori vaccine Drugs 0.000 title claims description 12
- 229960005486 vaccine Drugs 0.000 claims abstract description 59
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 16
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 16
- 230000000688 enterotoxigenic effect Effects 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 235000018102 proteins Nutrition 0.000 claims description 34
- 230000036039 immunity Effects 0.000 claims description 27
- 230000004927 fusion Effects 0.000 claims description 23
- 239000004005 microsphere Substances 0.000 claims description 23
- 238000000746 purification Methods 0.000 claims description 19
- 108010046334 Urease Proteins 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000005215 recombination Methods 0.000 claims description 10
- 230000006798 recombination Effects 0.000 claims description 10
- 239000003053 toxin Substances 0.000 claims description 10
- 231100000765 toxin Toxicity 0.000 claims description 10
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 abstract description 9
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 210000004877 mucosa Anatomy 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 18
- 230000009471 action Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 230000008521 reorganization Effects 0.000 description 15
- 230000009182 swimming Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 230000005847 immunogenicity Effects 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 230000000890 antigenic effect Effects 0.000 description 11
- 206010019375 Helicobacter infections Diseases 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 210000003000 inclusion body Anatomy 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 241001591005 Siga Species 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 101150061086 ureB gene Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 229940023064 escherichia coli Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 210000004211 gastric acid Anatomy 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000011020 pilot scale process Methods 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000016379 mucosal immune response Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000699694 Gerbillinae Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229940124551 recombinant vaccine Drugs 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000006052 feed supplement Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 101150018411 LTB gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- GFKPPJZEOXIRFX-UHFFFAOYSA-N TCA A Natural products CC(CCC(=O)O)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3 GFKPPJZEOXIRFX-UHFFFAOYSA-N 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 108010055409 ganglioside receptor Proteins 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930186900 holotoxin Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Abstract
Description
组别 | 攻毒后存活数(只) | 感染数(只) | 保护率(%) |
PBS组(磷酸盐缓冲1液pH7.0)2 UreB组3 UreB+LTB组4 UreB+LTA2B组5 UreB-LTB组 | 2830292730 | 2720192124 | -66.765.571.372.8 |
6 UreB+LTA2B组 | 29 | 27 | 91.6 |
组别 | 治疗后小鼠未检测到Hp只数 | 治疗后小鼠Hp量明显减少只数 | 定植数 |
LU治疗组(30只)两个亚单位混合组(30只)对照组(30只) | 21230 | 971 |
组别 | 受试人数 | 性别构成 | 平均年龄(岁) | |
男 | 女 | |||
安慰剂15mg/次30mg/次45mg/次合计 | 151148171153623 | 77698274317 | 74798979306 | 10.110.310.410.810.2 |
Claims (6)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100950940A CN100460013C (zh) | 2006-09-05 | 2006-09-05 | 口服重组幽门螺杆菌疫苗及其制备方法 |
ES07800872T ES2363875T3 (es) | 2006-09-05 | 2007-09-05 | Vacuna oral de helicobacter pylori recombinante y método de preparación de la misma. |
AT07800872T ATE510560T1 (de) | 2006-09-05 | 2007-09-05 | Oraler rekombinanter helicobacter-pylori-impstoff und sein herstellungsverfahren |
EP07800872A EP2082750B1 (en) | 2006-09-05 | 2007-09-05 | Oral recombinant helicobacter pylori vaccine and preparing method thereof |
JP2009526999A JP5327873B2 (ja) | 2006-09-05 | 2007-09-05 | リコンビナントヘリコバクターピロリの経口ワクチン及びその調製方法 |
US12/310,658 US8900594B2 (en) | 2006-09-05 | 2007-09-05 | Oral recombinant Helicobacter pylori vaccine and preparing method thereof |
PCT/CN2007/002655 WO2008040155A1 (zh) | 2006-09-05 | 2007-09-05 | 口服重组幽门螺杆菌疫苗及其制备方法 |
KR1020097006936A KR101100237B1 (ko) | 2006-09-05 | 2007-09-05 | 경구용 재조합 헬리코박터 파일로리 백신 및 그의 제조방법 |
HK10101022.8A HK1137337A1 (en) | 2006-09-05 | 2010-01-29 | Oral recombinant helicobacter pylori vaccine and preparing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100950940A CN100460013C (zh) | 2006-09-05 | 2006-09-05 | 口服重组幽门螺杆菌疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1927394A true CN1927394A (zh) | 2007-03-14 |
CN100460013C CN100460013C (zh) | 2009-02-11 |
Family
ID=37857625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100950940A Expired - Fee Related CN100460013C (zh) | 2006-09-05 | 2006-09-05 | 口服重组幽门螺杆菌疫苗及其制备方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8900594B2 (zh) |
EP (1) | EP2082750B1 (zh) |
JP (1) | JP5327873B2 (zh) |
KR (1) | KR101100237B1 (zh) |
CN (1) | CN100460013C (zh) |
AT (1) | ATE510560T1 (zh) |
ES (1) | ES2363875T3 (zh) |
HK (1) | HK1137337A1 (zh) |
WO (1) | WO2008040155A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130259888A1 (en) * | 2010-06-25 | 2013-10-03 | Ondek Pty Ltd | Means of controlling infection persistence of helicobacter pylori |
CN104023744A (zh) * | 2011-12-23 | 2014-09-03 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌免疫的稳定组合物 |
CN104160011A (zh) * | 2012-03-08 | 2014-11-19 | 索尼公司 | 用于核酸扩增反应的微芯片的制造方法 |
CN107184967A (zh) * | 2017-03-27 | 2017-09-22 | 广州市妇女儿童医疗中心 | 一种基于枯草芽孢载体的幽门螺杆菌口服疫苗 |
CN107298716A (zh) * | 2017-07-21 | 2017-10-27 | 成都亿妙生物科技有限公司 | 一种重组幽门螺杆菌蛋白疫苗及其制备方法 |
CN109280669A (zh) * | 2017-07-21 | 2019-01-29 | 刘开云 | 大肠杆菌不耐热肠毒素基因片段及其应用 |
CN110075290A (zh) * | 2018-01-25 | 2019-08-02 | 吴夙钦 | 流感黏膜疫苗组合物及其制备方法与应用 |
CN113144182A (zh) * | 2021-04-22 | 2021-07-23 | 成都亿妙生物科技有限公司 | 一种幽门螺杆菌口服缓释疫苗及其制备与应用 |
CN113151334A (zh) * | 2021-04-22 | 2021-07-23 | 成都亿妙生物科技有限公司 | 一种幽门螺杆菌LuxS六聚体重组蛋白的发酵和纯化工艺 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL218700B1 (pl) | 2012-03-29 | 2015-01-30 | Gdański Univ Medyczny | Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori |
EP2844301A2 (en) * | 2012-05-04 | 2015-03-11 | Ineb-instituto de Engenharia Biomédica | Microspheres for treating helicobacter pylori infections |
CN103990121B (zh) * | 2013-12-06 | 2015-07-08 | 上海联合赛尔生物工程有限公司 | 抗原嵌合体、抗原组合物、疫苗及其制备方法和试剂盒 |
KR102309957B1 (ko) * | 2015-01-09 | 2021-10-08 | 주식회사 엘지생활건강 | 캡슐화한 콘키올린을 함유한 화장료 조성물 |
WO2016178158A1 (en) * | 2015-05-07 | 2016-11-10 | Csir | Method for encapsulating pharmaceutical actives |
US10828358B2 (en) | 2015-12-14 | 2020-11-10 | Technische Universität München | Helicobacter pylori vaccines |
EP3272354A1 (en) | 2016-07-20 | 2018-01-24 | Technische Universität München | Agents and methods for the prevention or treatment of h. pylori infections |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073454A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2219201A1 (en) * | 1995-04-28 | 1996-10-31 | Oravax, Inc. | Multimeric, recombinant urease vaccine |
CN1188416A (zh) * | 1995-04-28 | 1998-07-22 | 奥拉瓦克斯有限公司 | 多体的重组尿素酶疫苗 |
US5837240A (en) * | 1995-04-28 | 1998-11-17 | Oravax-Merieux Co. | Multimeric, recombinant urease vaccine |
CA2335487A1 (en) | 1998-06-19 | 1999-12-23 | Merieux Oravax | Lt and ct in parenteral immunization methods against helicobacter infection |
US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
WO2001089456A2 (en) * | 2000-05-19 | 2001-11-29 | The Administrators Of The Tulane Educational Fund | Hybrid lt-a/ct-b holotoxin for use as an adjuvant |
JP2004528031A (ja) * | 2001-03-14 | 2004-09-16 | セントカー・インコーポレーテツド | 慢性閉塞性肺疾患関連の免疫グロブリン由来タンパク質、組成物、方法および用途 |
JP4902103B2 (ja) * | 2002-04-11 | 2012-03-21 | メディミューン・エルエルシー | 凍結乾燥フォームによる生物活性材料の保存 |
ITMI20031617A1 (it) * | 2003-08-06 | 2005-02-07 | Fond Carlo E Dirce Callerio Onlus | Microcapsule a doppio strato di polisaccaridi utilizzabili |
KR100673872B1 (ko) * | 2004-04-19 | 2007-01-25 | 학교법인 성균관대학 | 요로감염증의 예방 및 치료를 위한 재조합 디엔에이,플라스미드, 형질전환 미생물 및 경구용 백신 단백질 |
US20060141021A1 (en) * | 2004-12-29 | 2006-06-29 | Industrial Technology Research | Polymeric microspheres and method for preparing the same |
WO2007117339A2 (en) * | 2006-01-11 | 2007-10-18 | The United States Of America As Respresented By The Secretary Of The Navy | Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli |
-
2006
- 2006-09-05 CN CNB2006100950940A patent/CN100460013C/zh not_active Expired - Fee Related
-
2007
- 2007-09-05 KR KR1020097006936A patent/KR101100237B1/ko not_active IP Right Cessation
- 2007-09-05 AT AT07800872T patent/ATE510560T1/de not_active IP Right Cessation
- 2007-09-05 EP EP07800872A patent/EP2082750B1/en not_active Not-in-force
- 2007-09-05 JP JP2009526999A patent/JP5327873B2/ja not_active Expired - Fee Related
- 2007-09-05 WO PCT/CN2007/002655 patent/WO2008040155A1/zh active Application Filing
- 2007-09-05 ES ES07800872T patent/ES2363875T3/es active Active
- 2007-09-05 US US12/310,658 patent/US8900594B2/en not_active Expired - Fee Related
-
2010
- 2010-01-29 HK HK10101022.8A patent/HK1137337A1/xx not_active IP Right Cessation
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130259888A1 (en) * | 2010-06-25 | 2013-10-03 | Ondek Pty Ltd | Means of controlling infection persistence of helicobacter pylori |
US8992935B2 (en) * | 2010-06-25 | 2015-03-31 | Ondek Pty. Ltd. | Means of controlling infection persistence of Helicobacter pylori |
CN104023744A (zh) * | 2011-12-23 | 2014-09-03 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌免疫的稳定组合物 |
CN104160011A (zh) * | 2012-03-08 | 2014-11-19 | 索尼公司 | 用于核酸扩增反应的微芯片的制造方法 |
US9545630B2 (en) | 2012-03-08 | 2017-01-17 | Sony Corporation | Method for fabricating microchip for nucleic acid amplification reaction |
CN107184967A (zh) * | 2017-03-27 | 2017-09-22 | 广州市妇女儿童医疗中心 | 一种基于枯草芽孢载体的幽门螺杆菌口服疫苗 |
CN107298716A (zh) * | 2017-07-21 | 2017-10-27 | 成都亿妙生物科技有限公司 | 一种重组幽门螺杆菌蛋白疫苗及其制备方法 |
CN109280669A (zh) * | 2017-07-21 | 2019-01-29 | 刘开云 | 大肠杆菌不耐热肠毒素基因片段及其应用 |
CN110075290A (zh) * | 2018-01-25 | 2019-08-02 | 吴夙钦 | 流感黏膜疫苗组合物及其制备方法与应用 |
CN113144182A (zh) * | 2021-04-22 | 2021-07-23 | 成都亿妙生物科技有限公司 | 一种幽门螺杆菌口服缓释疫苗及其制备与应用 |
CN113151334A (zh) * | 2021-04-22 | 2021-07-23 | 成都亿妙生物科技有限公司 | 一种幽门螺杆菌LuxS六聚体重组蛋白的发酵和纯化工艺 |
CN113144182B (zh) * | 2021-04-22 | 2023-03-10 | 成都欧林生物科技股份有限公司 | 一种幽门螺杆菌口服缓释疫苗及其制备与应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2008040155A8 (zh) | 2009-07-30 |
HK1137337A1 (en) | 2010-07-30 |
EP2082750B1 (en) | 2011-05-25 |
ES2363875T3 (es) | 2011-08-18 |
KR101100237B1 (ko) | 2011-12-28 |
JP2010502199A (ja) | 2010-01-28 |
ATE510560T1 (de) | 2011-06-15 |
EP2082750A4 (en) | 2010-05-26 |
CN100460013C (zh) | 2009-02-11 |
US20110171315A1 (en) | 2011-07-14 |
US8900594B2 (en) | 2014-12-02 |
JP5327873B2 (ja) | 2013-10-30 |
EP2082750A1 (en) | 2009-07-29 |
WO2008040155A1 (zh) | 2008-04-10 |
KR20090053849A (ko) | 2009-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1927394A (zh) | 口服重组幽门螺杆菌疫苗及其制备方法 | |
CN100460014C (zh) | 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法 | |
CN1094640A (zh) | 以脲酶为基础的抗螺杆菌感染的疫苗 | |
CN101062410A (zh) | 一种肠出血性大肠杆菌o157:h7基因工程疫苗及其制备方法 | |
CN100579578C (zh) | 幽门螺杆菌抗原重组疫苗 | |
CN102276730A (zh) | 金黄色葡萄球菌IsdBid-TRAP融合蛋白制备方法及其应用 | |
CN1899609A (zh) | 肺炎球菌多糖蛋白偶联疫苗及其制备方法 | |
CN108273054A (zh) | 猪口蹄疫病毒O型、A型Fc多肽双价疫苗及其制备方法和应用 | |
CN1807452A (zh) | 幽门螺杆菌尿素酶B亚单位的Th表位肽、其编码DNA、疫苗及其应用 | |
CN1148449C (zh) | 链球菌毒素c突变体及其使用方法 | |
CN1833723A (zh) | 一种链球菌重组亚单位疫苗及其制备方法 | |
CN1748791A (zh) | 人和牲畜预防用出血性大肠杆菌o157:h7疫苗及制备方法 | |
CN108671227B (zh) | 一种预防猪链球菌感染的广谱多联亚单位疫苗 | |
CN1305525C (zh) | 人和易感动物o157菌基因工程多价亚单位疫苗及制备方法 | |
CN1255542C (zh) | 融合型幽门螺杆菌粘附素基因工程疫苗的制备方法 | |
CN1864746B (zh) | 幽门螺杆菌AhpC-NapA融合基因工程多价亚单位疫苗及其制备方法 | |
CN107737334A (zh) | 一种预防a型链球菌感染的广谱多联亚单位疫苗 | |
CN1657617A (zh) | 镰形扇头蜱RhcA和RhcB基因的克隆、表达和抗蜱免疫保护作用 | |
CN101062951A (zh) | 激发机体对鼠疫产生免疫力的融合蛋白及其编码基因与应用 | |
CN1163609C (zh) | 表达载体pBVIL1及其构建方法和用途 | |
CN1861792A (zh) | 编码大肠杆菌热敏毒素基因及其表达载体和用途 | |
CN1746184A (zh) | 天花粉蛋白突变体及其编码基因 | |
CN117018174A (zh) | 用于副鸡禽杆菌a型的酿酒酵母口服疫苗及应用 | |
CN115029291A (zh) | 表达鸭圆环病毒抗原Cap蛋白的重组禽多杀性巴氏杆菌,其制备方法和应用 | |
CN101063116A (zh) | 肺炎链球菌自溶酶蛋白及其原核表达纯化工艺和疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: WUHU KANGWEI BIOTECHNOLOGY CO., LTD. Free format text: FORMER NAME: CHONGQING KANGWEI BIOTECHNOLOGY LTD. |
|
CP03 | Change of name, title or address |
Address after: 241000, Anhui Province, Wuhu province Minsheng Road No. 26 Kay sail building, 18 floor Patentee after: WUHU KANGWEI BIOTECHNOLOGY CO., LTD. Address before: 400038 Chongqing Shapingba city gaotanyan Garden City Yan Yuyuan building B 7-5 Patentee before: Chongqing Kangwei biotechnology Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090211 Termination date: 20180905 |